All In Biotech

Drug Trial Radar · NCT04575597

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.

Last checked: Nov 19, 2026Latest source record: Jun 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,735 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,735

Actual

Start

Oct 19, 2020

Primary completion

May 5, 2022

Study completion May 5, 2022

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29

Conditions

  • Coronavirus Disease (COVID-19)

Interventions

  • MolnupiravirDrug

    Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

  • PlaceboDrug

    Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis)Time frame: Up to 29 days
  2. Number of Participants With an Adverse Event (AE)Time frame: Up to 318 days
  3. Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to 5 days

Locations

173 sites in 23 countries. Site status is shown where the registry gives one.

  • Phoenix Medical Group ( Site 1822)

    Peoria, Arizona

  • Ruane Clinical Research Group, Inc. ( Site 2406)

    Los Angeles, California

  • Men's Health Foundation ( Site 1820)

    Los Angeles, California

  • Carbon Health Technologies Inc ( Site 2505)

    North Hollywood, California

  • UC Davis Medical Center ( Site 1833)

    Sacramento, California

  • Emerson Clinical Research Institute ( Site 1828)

    Washington D.C., District of Columbia

  • JEM Research Institute ( Site 2508)

    Atlantis, Florida

  • Midway Immunology and Research Center ( Site 1837)

    Ft. Pierce, Florida

  • Indago Research & Health Center, Inc ( Site 1809)

    Hialeah, Florida

  • Advanced Research For Health Improvement LLC ( Site 1816)

    Immokalee, Florida

  • Advanced Medical Research, LLC ( Site 1864)

    Miami, Florida

  • Advanced Research For Health Improvement LLC ( Site 1813)

    Naples, Florida

  • Bliss Healthcare Services ( Site 1847)

    Orlando, Florida

  • Javara Inc. ( Site 1869)

    Albany, Georgia

  • IACT Health ( Site 1818)

    Columbus, Georgia

  • Javara Inc. ( Site 1868)

    Fayetteville, Georgia

  • Loretto Hospital ( Site 1886)

    Chicago, Illinois

  • Jadestone Clinical Research, LLC ( Site 2502)

    Laurel, Maryland

  • Michigan Center of Medical Research ( Site 2500)

    Farmington Hills, Michigan

  • University of Nebraska Medical Center ( Site 2414)

    Omaha, Nebraska

  • Amici Clinical Research LLC ( Site 2507)

    Raritan, New Jersey

  • University of New Mexico, Health Sciences Center ( Site 1819)

    Albuquerque, New Mexico

  • AXCES Research Group ( Site 2418)

    Santa Fe, New Mexico

  • Saint Hope Foundation, Inc. ( Site 1830)

    Bellaire, Texas

  • The Crofoot Research Center, Inc. ( Site 1812)

    Houston, Texas

  • Javara Inc. ( Site 1866)

    Sugar Land, Texas

  • Clinical Research Partners, LLC. ( Site 2503)

    Richmond, Virginia

  • Swedish Medical Center First Hill ( Site 1807)

    Seattle, Washington

  • Fred Hutchinson Cancer Center ( Site 1829)

    Seattle, Washington

  • Multicare Health System ( Site 1811)

    Spokane, Washington

  • Multicare Health System ( Site 1814)

    University Place, Washington

  • Medical College Of Wisconsin ( Site 2510)

    Milwaukee, Wisconsin

  • Clinica Independencia ( Site 3400)

    Vicente López, Buenos Aires, Argentina

  • Instituto Medico de la Fundacion Estudios Clinicos ( Site 3401)

    Rosario, Santa Fe Province, Argentina

  • Instituto de Infectologia Emilio Ribas ( Site 0153)

    São Paulo, Brazil

  • Centro de Pesquisa Clinica II - ICHC - FMUSP ( Site 0152)

    São Paulo, Brazil

  • Chronos Pesquisa Clínica ( Site 0155)

    Brasília, Federal District, Brazil

  • Santa Casa de Misericordia de Belo Horizonte ( Site 0150)

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital de Clinicas da Universidade Federal do Parana ( Site 0154)

    Curitiba, Paraná, Brazil

  • Hospital Tacchini ( Site 0157)

    Bento Gonçalves, Rio Grande do Sul, Brazil

Showing 40 of 173 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.